Use of antipsychotic medications in pediatric populations: what do the data say?
- PMID: 24258527
- PMCID: PMC4167011
- DOI: 10.1007/s11920-013-0426-8
Use of antipsychotic medications in pediatric populations: what do the data say?
Erratum in
- Curr Psychiatry Rep. 2014 Feb;16(2):432. Coleman, Karen A [corrected to Coleman, Karen J]
Abstract
Recent reports of antipsychotic medication use in pediatric populations describe large increases in rates of use. Much interest in the increasing use has focused on potentially inappropriate prescribing for non-Food and Drug Administration-approved uses and use amongst youth with no mental health diagnosis. Different studies of antipsychotic use have used different time periods, geographic and insurance populations of youth, and aggregations of diagnoses. We review recent estimates of use and comment on the similarities and dissimilarities in rates of use. We also report new data obtained on 11 health maintenance organizations that are members of the Mental Health Research Network in order to update and extend the knowledge base on use by diagnostic indication. Results indicate that most use in pediatric populations is for disruptive behaviors and not psychotic disorders. Differences in estimates are likely a function of differences in methodology; however, there is remarkable consistency in estimates of use by diagnosis.
Conflict of interest statement
Enid M. Hunkeler has patent applications pending for an individualized health care management system and a computer-implemented method for assisting a care partner in monitoring a patient with a chronic disease.
Similar articles
-
Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.Eur Child Adolesc Psychiatry. 2017 Apr;26(4):413-420. doi: 10.1007/s00787-016-0905-7. Epub 2016 Sep 13. Eur Child Adolesc Psychiatry. 2017. PMID: 27623818
-
Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth.J Am Acad Child Adolesc Psychiatry. 2017 Jan;56(1):59-66. doi: 10.1016/j.jaac.2016.10.005. Epub 2016 Oct 24. J Am Acad Child Adolesc Psychiatry. 2017. PMID: 27993230
-
Comparison of Unlicensed and Off-Label Use of Antipsychotics Prescribed to Child and Adolescent Psychiatric Outpatients for Treatment of Mental and Behavioral Disorders with Different Guidelines: The China Food and Drug Administration Versus the FDA.J Child Adolesc Psychopharmacol. 2018 Apr;28(3):216-224. doi: 10.1089/cap.2017.0079. Epub 2018 Jan 16. J Child Adolesc Psychopharmacol. 2018. PMID: 29336603
-
Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies.Acta Psychiatr Scand. 2010 Jan;121(1):4-10. doi: 10.1111/j.1600-0447.2009.01425.x. Epub 2009 Jun 25. Acta Psychiatr Scand. 2010. PMID: 20059452 Review.
-
A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents.Can J Psychiatry. 2012 Dec;57(12):717-21. doi: 10.1177/070674371205701202. Can J Psychiatry. 2012. PMID: 23228229 Review.
Cited by
-
Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.Eur Child Adolesc Psychiatry. 2016 Oct;25(10):1091-102. doi: 10.1007/s00787-016-0832-7. Epub 2016 Feb 26. Eur Child Adolesc Psychiatry. 2016. PMID: 26921232
-
Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder.J Autism Dev Disord. 2017 Jan;47(1):144-154. doi: 10.1007/s10803-016-2946-7. J Autism Dev Disord. 2017. PMID: 27817163 Free PMC article.
-
Effectiveness of lifestyle interventions for improving the physical health of children and adolescents taking antipsychotic medications: protocol for a systematic review and meta-analysis.BMJ Open. 2023 Oct 27;13(10):e073893. doi: 10.1136/bmjopen-2023-073893. BMJ Open. 2023. PMID: 37890972 Free PMC article.
-
Antipsychotic prescribing patterns in children and adolescents attending Australian general practice in 2011 and 2017.JCPP Adv. 2023 Nov 10;4(1):e12208. doi: 10.1002/jcv2.12208. eCollection 2024 Mar. JCPP Adv. 2023. PMID: 38486961 Free PMC article.
-
Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.Can J Psychiatry. 2017 Sep;62(9):635-647. doi: 10.1177/0706743717720197. Epub 2017 Aug 2. Can J Psychiatry. 2017. PMID: 28764561 Free PMC article. Review.
References
-
- Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13–23. Epub 2010/03/11. - PubMed
-
- Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics. Arch Gen Psychiatry. 2012:1–10. Epub 2012/08/08. Paper presents antipsychotic utilization estimates between 1993 and 2009 using nationally representative NAMCS data. Estimates are based on visits where a prescription occurred. Excellent discussion of reasons for practice variation in prescribing and increasing use over time. - PubMed
-
- Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135–41. Epub 2011/11/23. Study reports an almost fourfold increase in the rate of diabetes among youth using antipsychotic medications compared to youth using no psychotropic medications. - PubMed
-
- Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011;72(8):e26. Epub 2011/09/09. Seminal study on the side effects of antipsychotic medications in youth. - PubMed
-
- Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517–35. Epub 2011/12/15. Review of 34 published head-to-head and placebo-controlled studies in youth with psychotic and bipolar disorders of the effects of antipsychotic medications on weight and metabolic disorders. Describes metabolic effects and number-needed-to-harm for individual agents. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical